AUTL — Autolus Therapeutics Income Statement
0.000.00%
Last trade - 00:00
- $1.33bn
- $1.10bn
- $1.70m
2019 December 31st | 2020 December 31st | C2021 December 31st | C2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 20-F | 20-F | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 2.91 | 1.72 | 2.33 | 6.36 | 1.7 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 149 | 170 | 143 | 150 | 181 |
Operating Profit | -146 | -168 | -141 | -143 | -180 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -139 | -166 | -142 | -149 | -208 |
Provision for Income Taxes | |||||
Net Income After Taxes | -124 | -142 | -142 | -149 | -208 |
Net Income Before Extraordinary Items | |||||
Net Income | -124 | -142 | -142 | -149 | -208 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -124 | -142 | -142 | -149 | -208 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -2.81 | -2.74 | -1.97 | -1.56 | -1.18 |